How Much Does Mounjaro Cost in Nevada in 2026?

Nevada Retail Pricing for Brand-Name Mounjaro

The manufacturer list price set by Eli Lilly for Mounjaro is $1,023 per month regardless of dose strength, and Nevada retail pharmacies reflect this figure with minimal variation. This price applies to a four-week supply (four pre-filled pens) dispensed at any dose from 2.5 mg through 15 mg.

Nevada has no state-level prescription drug price cap that would lower this figure at the pharmacy counter. Unlike states with pharmaceutical transparency laws that force price justification filings, Nevada's current regulatory framework does not intervene in manufacturer pricing for GLP-1 receptor agonists. The wholesale acquisition cost (WAC) tracks closely to the retail number because Eli Lilly maintains uniform channel pricing for Mounjaro pens.

Patients paying cash should compare prices across Walgreens, CVS, Smith's (Kroger), and independent pharmacies in Las Vegas, Reno, and Henderson. Price differences between chains are typically under $20 for brand Mounjaro because the WAC leaves little room for markup variation. Mail-order pharmacies like Optum and Express Scripts may offer 90-day fills at a per-unit discount for patients whose plans allow it.

In the SURPASS-2 trial (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.58% and body weight by 12.4 kg at 40 weeks compared to semaglutide 1 mg 1. That efficacy data underpins Eli Lilly's pricing strategy and payer negotiations across all states including Nevada.

Nevada Medicaid and Mounjaro Coverage

Nevada Medicaid does not cover Mounjaro for weight management. The state's preferred drug list excludes tirzepatide for obesity indications, and prior authorization requests for off-label weight loss use are routinely denied.

For type 2 diabetes, coverage depends on the managed care organization (MCO) administering the patient's benefits. Nevada Medicaid operates through MCOs including Anthem Blue Cross Blue Shield, Molina Healthcare, and Health Plan of Nevada. Each MCO maintains its own formulary within state guidelines. As of early 2026, none of Nevada's Medicaid MCOs list Mounjaro as a preferred agent for type 2 diabetes. Step therapy requirements typically mandate failure on metformin plus a sulfonylurea or an SGLT2 inhibitor before a GLP-1 class drug receives authorization.

The FDA-approved prescribing information for Mounjaro limits the branded indication to type 2 diabetes as an adjunct to diet and exercise [2]. Zepbound, the same tirzepatide molecule approved specifically for chronic weight management, carries a separate NDC and a separate coverage determination. Nevada Medicaid has not added Zepbound to its formulary either.

Patients on Nevada Medicaid who need GLP-1 therapy for diabetes may have access to older agents like liraglutide (Victoza) or dulaglutide (Trulicity) through standard formulary channels. Dr. Robert Gabbay, Chief Scientific and Medical Officer at the American Diabetes Association, has stated: "Access barriers to newer diabetes medications disproportionately affect patients in state Medicaid programs, where formulary lag can exceed 18 months after FDA approval" 3.

Insurance Coverage for Mounjaro in Nevada

Commercial insurance plans in Nevada vary widely in their tirzepatide coverage. Large employer-sponsored plans through UnitedHealthcare, Cigna, Aetna, and Blue Cross Blue Shield of Nevada increasingly cover Mounjaro for type 2 diabetes with prior authorization. Coverage for weight management remains inconsistent.

Plans that do cover Mounjaro typically require:

• Confirmed diagnosis of type 2 diabetes with HbA1c above 7.0%
• Documentation of metformin trial (or intolerance)
• Prescriber attestation that lifestyle modification is concurrent
• Quarterly HbA1c or weight-loss documentation for renewal

Specialty tier placement is common. Patients with Mounjaro on specialty tier face coinsurance of 25% to 50% rather than a flat copay, which at list price translates to $256 to $512 per month out-of-pocket before reaching their deductible or out-of-pocket maximum.

Nevada's state employee health plan (PEBP, the Public Employees' Benefits Program) added limited GLP-1 coverage in 2025 for members with type 2 diabetes and BMI above 30. PEBP members should verify current formulary status through the plan's pharmacy benefit manager, which has historically been Express Scripts.

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends tirzepatide as a first-line pharmacotherapy option for adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities 4. This guideline is accelerating commercial payer coverage decisions nationally, though Nevada-specific implementation timelines vary by carrier.

The Eli Lilly Savings Card in Nevada

Eli Lilly's Mounjaro Savings Card reduces out-of-pocket costs to as low as $25 per monthly fill for patients with commercial insurance. The card is not valid for government-funded insurance including Medicare, Medicaid, Tricare, or VA benefits.

Eligibility requirements: the patient must have commercial or private insurance that covers Mounjaro (even with high cost-sharing), hold a valid prescription, and reside in the United States. Nevada residents with qualifying plans can activate the card at mounjaro.lilly.com or receive activation through their prescriber's office.

The savings card covers the difference between the patient's plan-required cost-sharing and $25, up to a maximum benefit of $573 per fill or $6,876 per calendar year. Once the annual cap is reached, the patient reverts to standard plan cost-sharing. For patients whose insurance requires a $300 copay, the card effectively saves $275 per month. For patients facing $500+ coinsurance charges, the card saves substantially more per fill but may exhaust the annual cap faster.

One limitation: the card does not help uninsured patients. Patients without any insurance coverage for Mounjaro cannot use the savings card to reduce the $1,023 cash price. Eli Lilly's separate Mounjaro patient assistance program exists for uninsured patients meeting income thresholds (typically below 400% of the federal poverty level), but approval takes 4 to 6 weeks and requires annual recertification.

Compounded Tirzepatide in Nevada: Legality and Pricing

Compounded tirzepatide is legal in Nevada through state-licensed 503A compounding pharmacies operating under a valid patient-specific prescription. Nevada Board of Pharmacy regulations permit 503A facilities to compound tirzepatide preparations when a prescriber determines that a commercially available product is not suitable for the individual patient (for example, due to dose customization needs or documented allergy to an inactive ingredient in the branded product).

Pricing for compounded tirzepatide in Nevada averages $249 per month, roughly 75% less than brand Mounjaro. This price point reflects the cost structure of 503A pharmacies purchasing bulk tirzepatide active pharmaceutical ingredient (API) and compounding individual vials or syringes per prescription.

Key distinctions between compounded and brand-name tirzepatide:

• Compounded preparations are not FDA-approved products
• Potency, sterility, and stability testing varies by pharmacy
• No manufacturer savings card or rebate programs apply
• Dose flexibility may exceed branded pen options (e.g., doses between standard steps)
• Vial-and-syringe format requires patients to draw and inject manually

The FDA's position on compounded GLP-1 agonists has shifted during 2025-2026. During the tirzepatide shortage period, 503A and 503B pharmacies compounded freely under shortage exemptions. Post-shortage, the FDA has signaled enforcement discretion timelines that vary. Nevada patients should confirm with their compounding pharmacy that their source API meets USP standards and that the pharmacy holds current Nevada Board of Pharmacy licensure 5.

Nevada-based 503A compounding pharmacies serving tirzepatide patients include facilities in Las Vegas, Reno, and Henderson. Several national telehealth platforms also ship compounded tirzepatide to Nevada addresses from out-of-state 503A pharmacies licensed in their home states, which is permissible under federal law when the prescription is patient-specific.

Telehealth Access to Mounjaro in Nevada

Nevada permits telehealth prescribing of Mounjaro and compounded tirzepatide without requiring an in-person visit first. The state's telehealth parity laws, updated in 2023, allow audio-video consultations to establish a prescriber-patient relationship sufficient for controlled and non-controlled substance prescribing.

Tirzepatide is not a controlled substance, which simplifies the telehealth pathway. Nevada-licensed physicians, nurse practitioners, and physician assistants can prescribe Mounjaro or compounded tirzepatide after a synchronous video consultation that includes:

• Medical history review including contraindications (personal or family history of medullary thyroid carcinoma, MEN2 syndrome)
• Current medication reconciliation
• BMI calculation or documented weight and height
• Discussion of injection technique and titration schedule

National telehealth platforms operating in Nevada include Ro, Hims, Found, Calibrate, and Henry Meds, among others. Pricing for telehealth-prescribed compounded tirzepatide packages (consultation plus medication plus shipping) ranges from $299 to $499 per month depending on dose and platform. Some platforms include the prescriber visit in their monthly medication fee while others charge separately.

The Endocrine Society has endorsed telehealth as appropriate for obesity pharmacotherapy management, noting that remote monitoring with periodic lab work produces outcomes comparable to in-person management for stable patients on GLP-1 therapy [6].

Cost Comparison: All Nevada Tirzepatide Options

A direct comparison of monthly costs for a Nevada patient at the 10 mg maintenance dose:

Brand Mounjaro (no insurance): $1,023. No savings card eligible without insurance.

Brand Mounjaro (commercial insurance, no savings card): $100 to $512, depending on tier placement and cost-sharing structure.

Brand Mounjaro (commercial insurance + Lilly savings card): $25 per fill while annual benefit cap remains.

Compounded tirzepatide (503A, cash pay): $249 average. Some pharmacies price lower at $199 for lower doses.

Telehealth platform bundle (compounded, all-inclusive): $299 to $499 including prescriber fees, medication, and shipping.

Patient assistance program (uninsured, income-qualifying): $0 if approved through Lilly's program.

For patients weighing brand versus compounded options, the clinical evidence base applies to the branded product specifically. The SURPASS program trials (SURPASS-1 through SURPASS-5) enrolled patients on manufactured tirzepatide with standardized potency and sterility. Compounded versions have not undergone equivalent clinical trial evaluation, though the active molecule is identical 1.

How to Reduce Your Mounjaro Cost in Nevada

Start by verifying insurance coverage. Call the number on your pharmacy benefit card and ask specifically whether tirzepatide (brand name Mounjaro, NDC starts with 00002) is on formulary. Request the tier, prior authorization requirements, and applicable cost-sharing.

If covered with high cost-sharing, activate the Lilly savings card before your first fill. Your pharmacy can process both your insurance and the savings card in a single transaction at the point of sale.

If not covered or uninsured, evaluate compounded tirzepatide from a Nevada-licensed 503A pharmacy. Ask the pharmacy for their most recent third-party potency and sterility testing certificates. The Nevada Board of Pharmacy maintains a public license verification tool where patients can confirm pharmacy licensure status.

If your income falls below 400% FPL ($62,400 for an individual in 2026), apply for Eli Lilly's patient assistance program. The application requires income documentation, a prescriber signature, and proof of insurance denial or lack of coverage.

For patients with type 2 diabetes specifically, an appeal letter citing the Endocrine Society guideline and SURPASS-2 superiority data may overturn an initial insurance denial. Include HbA1c values, prior medication failures, and the specific guideline recommendation language. Nevada's external review process through the Division of Insurance provides a second-level appeal pathway if the internal plan appeal fails 7.

According to a 2024 analysis in Diabetes Care, 34% of initial prior authorization denials for GLP-1 receptor agonists are overturned on first appeal when supported by clinical documentation meeting guideline criteria 8.

Nevada-Specific Pharmacy and Regulatory Considerations

Nevada's Board of Pharmacy does not impose additional state-level restrictions on tirzepatide dispensing beyond federal requirements. The state allows pharmacists to perform therapeutic substitution only when explicitly authorized by the prescriber, meaning a prescription written for "Mounjaro" cannot be automatically substituted with compounded tirzepatide without prescriber consent.

Nevada participates in the Prescription Drug Monitoring Program (PDMP), but tirzepatide is not a monitored substance. No PDMP check is required before dispensing. This distinguishes GLP-1 prescribing from scheduled medications like phentermine, which some patients may have used previously for weight management.

For patients near state borders (Wendover, Laughlin, Mesquite), filling prescriptions in neighboring Utah, Arizona, or California does not typically yield price advantages for brand Mounjaro due to uniform manufacturer pricing. However, compounded tirzepatide pricing may differ across state lines based on local 503A pharmacy competition and overhead costs.

The Nevada Attorney General's Consumer Protection Division has issued guidance reminding patients to verify that any online pharmacy shipping tirzepatide to Nevada addresses holds appropriate licensure. Patients should look for NABP (National Association of Boards of Pharmacy) accreditation or direct Nevada licensure verification before purchasing from unfamiliar online sources 9.